Genus Capital Management Inc. Sells 989 Shares of Insulet Corporation $PODD

Genus Capital Management Inc. cut its position in Insulet Corporation (NASDAQ:PODD) by 5.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,019 shares of the medical instruments supplier’s stock after selling 989 shares during the quarter. Genus Capital Management Inc.’s holdings in Insulet were worth $5,033,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. American Century Companies Inc. raised its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares in the last quarter. Nuveen LLC acquired a new position in shares of Insulet during the 1st quarter worth $74,163,000. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Insulet by 1,316.5% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after buying an additional 179,850 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after buying an additional 178,976 shares in the last quarter. Finally, AustralianSuper Pty Ltd raised its holdings in shares of Insulet by 487.5% during the 2nd quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after buying an additional 170,247 shares in the last quarter.

Insider Transactions at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on PODD shares. JPMorgan Chase & Co. boosted their price target on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Jefferies Financial Group reissued a “buy” rating on shares of Insulet in a report on Thursday, August 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Stifel Nicolaus started coverage on Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target for the company. Finally, Wells Fargo & Company boosted their price target on Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $352.11.

Insulet Price Performance

Shares of PODD opened at $320.27 on Wednesday. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $353.50. The business has a 50-day simple moving average of $326.15 and a two-hundred day simple moving average of $308.69. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $22.54 billion, a PE ratio of 97.35, a PEG ratio of 2.64 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same quarter in the prior year, the firm earned $0.55 EPS. The business’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.